<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/EF25BFEC-2767-4C05-93C1-5C5985564AEC"><gtr:id>EF25BFEC-2767-4C05-93C1-5C5985564AEC</gtr:id><gtr:name>Sofmat Ltd</gtr:name><gtr:address><gtr:line1>UNIT 1, NELTHORPE ARMS BUSINESS COURT , 1 BRIDGE STREET</gtr:line1><gtr:city>BRIGG</gtr:city><gtr:postCode>DN20 8LN</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EF25BFEC-2767-4C05-93C1-5C5985564AEC" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>EF25BFEC-2767-4C05-93C1-5C5985564AEC</gtr:id><gtr:name>Sofmat Ltd</gtr:name><gtr:address><gtr:line1>UNIT 1, NELTHORPE ARMS BUSINESS COURT , 1 BRIDGE STREET</gtr:line1><gtr:city>BRIGG</gtr:city><gtr:postCode>DN20 8LN</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>78063.0</gtr:offerGrant><gtr:projectCost>130105.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/0B554299-5DB1-4FF6-8C14-3539D6012521"><gtr:id>0B554299-5DB1-4FF6-8C14-3539D6012521</gtr:id><gtr:firstName>Sue</gtr:firstName><gtr:surname>Rainton</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=710491"><gtr:id>1C98AC0F-5366-453A-B79E-807BF203CE29</gtr:id><gtr:title>Development of prototype to demonstrate the production options for the use of SofMat 3D technology in sequential marking within the pharmaceutical sector.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Concept</gtr:grantCategory><gtr:grantReference>710491</gtr:grantReference><gtr:abstractText>The cost to the UK economy of counterfeit products has been estimated at &amp;pound;9billion per year
(ICC Commercial Crime Services Ref CIB-9-0556 11-11-2009). All areas of the economy are
affected by counterfeit goods, from branded clothing through critical goods such as
pharmaceuticals and automotive &amp;amp; aerospace parts. No industry sector is immune from the
effects of counterfeit products. The problem is seen as so great in the pharmaceutical sector
that an annual conference (Anti Counterfeiting for Pharmaceuticals, May 2013) has been
organised, devoted to securing the pharmaceutical supply chain to stop entry of counterfeit
drugs &amp;amp; devices. Much time has also been devoted to globalise the legislation dealing with
anti-counterfeit pharmaceutical products but no simple point of use method of product
authentification has been developed so far according to information from the World Health
Organisation (www.who.int/impact).
The SofMat project will be used to implement pharmaceutical sector suggestions to develop a
sequential 3D marking system that will be used side by side with the existing batch process.
The process can be used to sequentially mark drugs without adulterating the product ensuring
that FDA legislations can be easily complied with. The process is unique in the marketplace
&amp;amp; simple in execution, using a reader with smartphone technology which will be developed
during this project. This product for the first time places the identification of counterfeit
goods within the supply chain rather than in the hands of the producers or governmental
agencies. This allows a wider scope for identification &amp;amp; removal of counterfeit goods by
allowing easy identification throughout the supply chain.
As a follow up to this Pharmaceutical project the Company will determine whether the
technology can be utilised in other sectors, eg: automotive &amp;amp; aerospace. These next markets
have been selected using a market report that identified these as the next prime target sectors.</gtr:abstractText><gtr:fund><gtr:end>2015-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2014-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>78063</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">710491</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>